Carolina Legarda, 4 th year medical student Arrow Project, The Multiple Sclerosis Center. Supervisors: Dr. Shay Menascu Dr.

Similar documents
DOWNLOAD OR READ : MULTIPLE SCLEROSIS THE HISTORY OF A DISEASE PDF EBOOK EPUB MOBI

Progress in MS: Current and Emerging Therapies. Presented by: Dr. Kathryn Giles, MD MSc FRCPC Cambridge, Ontario, Canada

Clinical and research application of MRI in diagnosis and monitoring of multiple sclerosis

THE NATURAL HISTORY OF MS: DIAGNOSIS, CLINICAL COURSE, AND EPIDEMIOLOGY

Pediatric MS treatments: What do you start with, when do you switch?

Choices. Types of MS. Read me

MEDIA BACKGROUNDER. Multiple Sclerosis: A serious and unpredictable neurological disease

PEDIATRIC MULTIPLE SCLEROSIS CLINICAL AND TRANSCRIPTIONAL ASPECTS M U L T I P L E S C L E R O S I S C E N T E R

Carolyn Taylor, M.D. Swedish Neuroscience Center

MAVENCLAD. (cladribine tablets) MS Treatments. Produced by Lind Publishing, Inc.

MS Treatments Aubagio TM

When should disease-modifying treatments be discontinued in patients with multiple sclerosis? An evidence-based review with expert recommendations.

DOWNLOAD OR READ : MULTIPLE SCLEROSIS HOW I WON THE BATTLE PDF EBOOK EPUB MOBI

MRI in Differential Diagnosis. CMSC, June 2, Jill Conway, MD, MA, MSCE

Roche s OCREVUS (ocrelizumab) approved in Switzerland for primary progressive and relapsing forms of multiple sclerosis

TECFIDERA (dimethyl fumarate) oral capsule

Thinking and Memory in MS

Investor Update. Downloads. Services PDF. Basel, 17 July 2017

COPYRIGHT 2012 THE TRANSVERSE MYELITIS ASSOCIATION. ALL RIGHTS RESERVED

EMA confirms recommendations to minimise risk of brain infection PML with Tysabri

Neurological Assessment for Multiple Sclerosis and Extended Disability Scale Score

1 MS Lesions in T2-Weighted Images

Disease modifying drugs. a guide to Mavenclad

Research Article Optic Nerve and Spinal Cord Are the Major Lesions in Each Relapse of Japanese Multiple Sclerosis

MULTIPLE SCLEROSIS - REVIEW AND UPDATE

Tumefactive multiple sclerosis lesions: Diagnostic challenge for the radiologist

Relapses Matter A GUIDE TO REPORTING MULTIPLE SCLEROSIS SYMPTOMS

Media Release. Basel, 10 November 2017

Overview 12/8/2008. Simplifying Neurology for critical illness claims. Multiple Sclerosis. Basics Advances in diagnosis and treatment.

Treating MS. New medicines, strong evidence, better practice? September 2015

AUBAGIO (teriflunomide) oral tablet

Disease of Myelin. Reid R. Heffner, MD Distinguished Teaching Professor Emeritus Department of Pathology and Anatomy January 9, 2019

GILENYA (fingolimod) oral capsule

MULTIPLE SCLEROSIS IN Managing the complexity of multiple sclerosis. Olga Ciccarelli and Alan Thompson

DOWNLOAD OR READ : MULTIPLE SCLEROSIS PDF EBOOK EPUB MOBI

First steps for success.

Childhood Stroke: Risk Factors, Symptoms and Prognosis

Hot Topics Multiple Sclerosis. Natalie Parks, MD, FRCPC Assistant Professor, Dalhousie University June 27, 2018

CyberKnife. Pre-treatment information for patients MEDICAL CLINIC

How is primary breast cancer treated?

Fast Facts: Multiple Sclerosis

Kaspar Rufibach Methods, Collaboration, and Outreach Group (MCO) Department of Biostatistics, Roche Basel

What Is Nuclear Medicine?

Multiple Sclerosis. What is multiple sclerosis? What is the cause? What are the symptoms?

Adv Pathophysiology Unit 2: Neuro Page 1 of 8

Epidemiology, Diagnosis, Natural History & Clinical Course

New Insights on Optic Neuritis in Young People

Hoa Van Le, MD, PhD (Presenter) PAREXEL International ISPOR 22nd Annual International Meeting, Boston, MA. May 23, 2017

Locations: Casa Grande, Gilbert, Mesa, Phoenix Phone: 1(855)

Chapter One: Introduction to Clinical Trials

Clinically Isolated Syndrome of Early Onset Multiple Sclerosis in a Sample of Iraqi Patients

Demyelinating Diseases: Multiple Sclerosis January 10, 2018 Dr. Ostrow

Stereotactic radiotherapy for meningiomas using CyberKnife

LOOKING AHEAD: THE FUTURE OF MULTIPLE SCLEROSIS* Amit Bar-Or, MD, FRCP(C), MSc PARADIGM SHIFTS AND EMERGING CONCEPTS

Get on with life, we ll see you. in 6 months. Living your life your way with MS

Pediatric Brain Tumors: Updates in Treatment and Care

GILENYA (fingolimod) oral capsule

Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Neuromyelitis Optica in Singapore

THE DIFFICULTIES IN MAKING A DIAGNOSIS OF CJD

THE NATURAL HISTORY OF MS: DIAGNOSIS, CLINICAL COURSE, AND EPIDEMIOLOGY

Deep Breath Hold Technique

Secondary School Children who have Dysfluent Speech (Stammering/Stuttering).

DRG STIMULATION FOR CHRONIC PAIN FOCUS ON YOUR LIFE NOT YOUR PAIN

Case #1. Inter-ictal EEG. Difficult Diagnosis Pediatrics. 15 mos girl with medically refractory infantile spasms 2/13/2010

STROKE INTRODUCTION OBJECTIVES. When the student has finished this module, he/she will be able to:

Teen depression: Large study finds girls have the highest risk

Demyelinating Diseases of the Brain

Provider Led Entity. CDI Quality Institute PLE Multiple Sclerosis (MS) AUC

Pancreatic Cancer: Associated Signs, Symptoms, Risk Factors and Treatment Approaches

INTRODUCTION. 1.

Update on Pediatric Brain Tumors

CNS pathology Third year medical students. Dr Heyam Awad 2018 Lecture 4: Myelin diseases of the CNS

Local Natalizumab Treatment Protocol

ADD / ADHD in Children

Actualização no diagnóstico e tratamento das doenças desmielinizantes na infância. Silvia Tenembaum

MRI diagnostic criteria for multiple sclerosis: an update

Collaborative Consultation Interdisciplinary Treatment of Multiple Sclerosis

Medication Policy Manual. Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013

Nuclear Medicine Bone Imaging

Interesting Pediatric ultrasound cases. Presented by: Falguni Patel (RDMS, RVT)

Multiple Sclerosis. Biology 12 Nervous System Project

MULTIPLE SCLEROSIS PROFILE

Magnetic Resonance Imaging of Neuromyelitis Optica (Devic s Syndrome)

Lung Surgery: Thoracoscopy

MRI in Multiple Sclerosis Features of Cerebral Atrophy with special focus on Multiple Sclerosis. E.W. Radue K. Bendfeldt Till Sprenger

Life Long Brain Health and DMT Comparative Effectiveness

European Commission Grants Approval for Mavenclad (Cladribine Tablets)

PEDIATRIC MULTIPLE SCLEROSIS

Endpoints in a treatment trial in NMO: Clinician s view. Anu Jacob Consultant Neurologist The Walton Centre, Liverpool,UK

NIH Public Access Author Manuscript Arch Neurol. Author manuscript; available in PMC 2008 November 5.

Stuttering. Risk factors that predict a chronic problem rather than spontaneous recovery include:

Sacroiliac Joint Imaging

Clinician s view of Benefit-Risk

Potential Rebalancing of the Immune System by Anti-CD52 Therapy

Program Highlights. A multidisciplinary AAN working group identified areas for improvement in the diagnosis and management of patients with MS

Role of MRI in acute disseminated encephalomyelitis

MRI in MS: the radiologist perspective

Regressions usually happen at the following ages 4 months, 8 months, 12 months, 18 months, 2 years.

What is Multiple Sclerosis? Gener al information

The Polarity of Dyspraxia and ADHD

Transcription:

Carolina Legarda, 4 th year medical student Arrow Project, The Multiple Sclerosis Center Supervisors: Dr. Shay Menascu Dr. Shmuel Miron

MRI parameters for prediction of conversion of clinically isolated syndromes to MS in children

MRI parameters for prediction of conversion of clinically isolated syndromes to MS in children

MRI parameters for prediction of conversion of clinically isolated syndromes to MS in children

MS is a chronic inflammatory demyelinating disease. Its cause is still unknown. Pathophysiology is immune mediated damage to the CNS, in particular the axons of nerves, caused by disruption of the BBB and inflammation which leads to focal demyelination. Childhood MS or pediatric MS, is apperance before the age of 18, 19, or 21. There is still no consensus. It is accepted to divide MS into 3 age groups: Childhood MS <12 Juvenile MS 12-18 Adult MS >18 Until a decade ago it was a largely unknown disease. Awareness is growing nowadays. There have been cases reported as young as 4 y.o.

2.7-5% have an onset in the pediatric age range, with onset generally being in the teenage years. Under age 10 represent about 0.2% to 0.9% of the total number of cases. The incidence in Israel is 0.1/100,000. Similar to adults with MS, girls are disproportionately represented, though ratios vary with age. Female-to-male ratios: >6-0.8:1. 6-10 - 1.6:1. <10-2:1. Children, in contrast to adults, almost exclusively present with relapsing-remitting disease.

Is the disease less or more aggressive in children? Progress to significant disability is much slower in children in the same follow up time. There is a more active inflammatory process. Second attack at a shorter time interval and higher relapse rate during first years. Recovery from relapse is also more rapid. Brain plasticity in children allows better recovery from damage.

MRI parameters for prediction of conversion of clinically isolated syndromes to MS in children

We don t know who will progress and how soon First neurological event CIS? Second neurological event MS

Why do we want to know who will progress and who won t? Diagnose & treat early Children progress slowly, but they become disabled at a younger age. Starting sooner makes them gain disability in their 20 s-40 s. Currently, for the child who presents with a first inflammatory demyelinating event, we are unable to predict if he will subsequently remain asymptomatic or develop the lifelong disease of MS.

Our study is looking for parameters in MRI that can answer these questions

The study MRI why?

The study MRI is a sensitive, non-invasive, no radiation means of tracking MS pathology. Pediatric patients are scanned periodically, what makes these characteristics to be of such value. The questions we want to answer: 1. What are the differences in the MRI of children that developed RRMS to those who did not? 2. What can the first MRI of a patient tell us about his future?

1 st Stage Patients between 0-20 y/o since 1995 127 patients High quality MRI s since 2007 62 patients Analysis of 2 scans for each patient: 1. MRI around CIS diagnosis 2. MRI around MS diagnosis

2 nd Stage

Lesion count - manual

Lets try one

How can we know the lesion location?

Assesing the degree of accuracy 1. Comparison to MSET count. 2. Comparison to the radiologists analysis. 3. Review of a random sample of patients. 4. Comparison to the count of the technician at the MS Center.

What data do we have? 1. Number of lesions 2. Location of lesions 3. Volume of each lesion and total volume of lesions

The Database

62 patients 38 MS group 24 control group CIS NMO ON 25 girls 13 boys 15 girls 9 boys 1.9 : 1 1.7 : 1

How do we know if our groups are comparable? How to normalize data?

Age at CIS 9 Ages of patients - MS group Ages of patients - control group 8 8 7 7 6 6 5 5 4 4 3 3 2 2 1 1 0 8 9 10 11 12 13 14 15 16 17 18 19 0 8 9 10 11 12 13 14 15 16 17 18 19

Follow up time MS group control group

Time from CIS to 1 st MRI CIS MS 0 6 months 1 year Is the first MRI close enough to CIS?

Normalizing difficulties Patient O. 12 y.o. girl presented with unspecific symptoms (vertigo) that resumed after fluid reconstitution and rest. This is her MRI:

Do these lesions look like MS? What does it look like? Leukodystrophy? Metabolic disease? Patient was taken out of study.

How quick is progression?

Age at MS diagnosis

Results

Results

Results

Results

Time from MRI #1 to MRI #2 12 MS group 6 control group 10 5 8 4 6 3 4 2 2 1 0 0

Something to think about Little is known about the ethiology of MS. Because children may be closer to the inciting events in MS, research pediatric MS may hold the key to understanding the cause of the disease itself. Thank you for listening.